Welcome
to
the
future
of
neurotherapeutics.
Our Mission
Around the world, millions are losing memories, identities, and futures to brain diseases we still cannot stop. It is a crisis advancing more rapidly than scientific progress can currently match.
But, the past does not have to define our future.
Sculpta is forging a bold new path with the development of Protein SculptingTM drugs, powered by cutting edge technology, scientific excellence, and a relentless spirit of urgency. Humanity cannot wait any longer.
Discover how we are challenging the status quo by reshaping the future of brain health.
Our Platform
ADVANCED NEURAL TISSUE ANALYSIS
Quality over quantity
Single cell genomics has revolutionized biological discovery, yet quality is often sacrificed for quantity. The most widely used platforms capture only the very ends of transcripts. AI models trained on this inaccurate data are not capturing disease-associated changes.
Sculpta’s platform captures full-length transcripts, powering our ATLAS AI-platform that is driving unique insights into the neurobiology of human disease.
ACCURATE PRE-CLINICAL MODELS
Human models for human disease
The associations between human nucleotide variants and disease are critical for the discovery of new targets. We are mining non-coding human variants and interpreting findings with our functional transcriptomics data to lead new target discovery in Alzheimer’s, Parkinson’s, neurodevelopment, and amyotrophic lateral sclerosis.
Instead of turning to mouse models, we use human stem cell derived models called organoids to accurately study disease pathophysiology.
A BOLD, NEW APPROACH
Protein Sculpting Therapeutics
Other companies try to drug proteins in the brain to treat disease. We change them.
Sculpta is the pioneer in Protein SculptingTM therapeutics, drugs that change the structure and function of disease-causing proteins in the brain using programmable RNA medicines.
We move beyond “up/down” genomic medicines, offering safer, more specific, and more effective therapies for devastating brain disorders, brought to patients faster.
Team
Neal Amin, MD, PhD
Founder | CEO
Mislav Acman
Senior Computational Biologist
Amina Khan, PhD
Research Associate
Bryan van Nimwegen, PhD
Computational Biologist
Joshua Berlind
Scientist
Joshua Berlind
Scientist
Neal Amin
Founder | CEO
Mislav Acman
Senior Computational Biologist
Amina Khan
Research Associate
Bryan van Nimwegen
Computational Biologist
Joshua Berlind
Scientist
Rahul Atmaramani
Senior Scientist
Max Beyman
Operations Associate
Investors
News
March 2025
New Publication in Neuron
March 2025
Sculpta Closes $2.6M Funding Round
Sculpta has successfully secured $2.6M in pre-seed funding from six venture capital groups and six angels to accelerate the the development of protein sculpting therapies for devastating brain disorders.
April 2025
New Publication in Nature
April 2025
New Publication in Nature
Neal Amin, CEO
Groundbreaking work on modeling human neurosensation for drug development with contributions from Sculpta CEO and Founder Neal Amin.
March 2025
Sculpta Closes $2.6M Funding Round
Sculpta has successfully secured $2.6M in pre-seed funding from six venture capital groups and six angels to accelerate the the development of protein sculpting therapies for devastating brain disorders.
March 2025
New Publication in Neuron
Joshua Berlind, Scientist
Research led by Sculpta scientist Joshua Berlind discovers excitotoxicity pathway in tau-opathies using advanced human brain organoid technology.